Merging medtech titans Medtronic and Covidien are preparing to host the 1st of 4 Integration Summits, scheduled later this month.
A senior executive at Medtronic, vice president of corporate development Chris Cleary, explains how Covidien played "scrappy" upstart all the way to a $43 billion payout.
Covidien begins enrolling patients in clinical trials for its Pipeline embolization system as well as all its endovascular stroke devices.
Covidien (NYSE:COV) announced today that it enrolled the 1st patients in a pair of clinical trials evaluating the company's neurovascular technologies.
Washington D.C. is preparing to move on efforts to penalize companies that move their headquarters overseas to benefit from lower corporate tax rates.
Covidien penetrates home-based patient monitoring through an agreement licensing its ZephyrLIFE telehealth solutions to Geneia for integration into their @Home platform.
Medtech titan Covidien (NYSE:COV) is breaching new ground in home care with its ZephyrLIFE remote monitoring platform, agreeing to license the technology to healthcare solutions company Geneia.
Here's a look at some of the top Wall Street stories for medical device companies this week: Renal denervation isn't dead, despite Medtronic trial's failure; Baxter says HQ will stay in Illinois, stays coy on Boston plans; Private equity owners rebrand KCI, Systagenix, LifeCell as Acelity
, Apax Partners
, Baxter International
, Boston Scientific
, Centaur Guernsey
, Kinetic Concepts Inc.
, Kona Medical
, LifeCell Corp.
, ReCor Medical
, St. Jude Medical
, Systagenix Wound Management Inc.
Here's a look at some of the top regulatory stories for medical device companies this week: Covidien acquires Sapheon and its VenaSeal varicose vein treatment; Medtronic to cover $58M tax tab for top execs in Covidien buy; Report: J&J puts Cordis on the block; Another Covidien shareholder sues over Medtronic deal; Allergan accedes to special meeting, asks court to block Valeant's vote